Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis

Duc Binh Phan; Anthony Bewley; Philip Laws; Teena Mackenzie; Catherine Smith; Christopher Em Griffiths; Mark Lunt; Richard B. Warren; Zenas Z N Yiu

doi:10.1001/jamadermatol.2025.0055

Related publications

Article2023

P66 Uptake of biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologics and Immunomodulators Register

Duc Binh Phan, Anthony Bewley, Catherine Smith, Teena Mackenzie, Christopher Em Griffiths, Mark Lunt, Richard B. Warren, Zenas Z N Yiu

Article2023

004 Does methotrexate affect treatment persistence or effectiveness of adalimumab for psoriasis? A trial emulation cohort study

Zenas Z N Yiu, Catherine Smith, Philip Laws, Philip Hampton, Christopher Em Griffiths, Richard B. Warren

Article2019

Persistence and effectiveness of systemic therapies for psoriasis

K.J. Mason, S. Williams, Zenas Z N Yiu, Kathleen McElhone, Darren M. Ashcroft, C. Elise Kleyn, Zarif K. Jabbar‐Lopez, Caroline Owen, Nick J. Reynolds, Catherine Smith, Nina Wilson, Richard B. Warren, Christopher Em Griffiths

Article2009

Adalimumab for the treatment of psoriasis

Richard B. Warren, Christopher Em Griffiths

Article2022

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Zenas Z N Yiu, G Becher, Brian Kirby, Philip Laws, Nick J. Reynolds, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Fiona Browne, Ian Evans, Elise Kleyn, Linda Lawson, Kathleen McElhone, Teena Mackenzie, Tess McPherson, Ruth Murphy, Caroline Owen, Eleanor Pearson, Josh Richards, Mark Lunt, A. David Burden, Oras Alabas,